[{"Assets_0_Q2_USD":4019965000.0,"CommonStockSharesConverted_0_Q2_shares":175248847.0,"CommonStockSharesOutstanding_0_Q2_shares":175248847.0,"EarningsPerShareBasic_1_Q2_USD":-0.21,"EarningsPerShareBasic_2_Q2_USD":-0.31,"NetIncomeLossConverted_1_Q2_USD":-36833000.0,"NetIncomeLossConverted_2_Q2_USD":-53123000.0,"NetCashProvidedByUsedInOperatingActivitiesConverted_2_Q2_USD":-61663000.0,"RevenuesConverted_1_Q2_USD":315926000.0,"RevenuesConverted_2_Q2_USD":618116000.0,"StockholdersEquity_0_Q2_USD":2795579000.0,"Ticker":"BMRN","CIK":"1048477","name":"BIOMARIN PHARMACEUTICAL INC","OfficialName":"BioMarin Pharmaceutical Inc. Common Stock","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"14899091235.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20170802"}]